Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zylox-Tonbridge Medical Technology Co's Return-on-Tangible-Equity or its related term are showing as below:
FRA:818'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -47.1 Med: -3.51 Max: 8.02
Current: 7.97
During the past 7 years, Zylox-Tonbridge Medical Technology Co's highest Return-on-Tangible-Equity was 8.02%. The lowest was -47.10%. And the median was -3.51%.
FRA:818's Return-on-Tangible-Equity is ranked better than 59.71% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.09
vs FRA:818: 7.97
Zylox-Tonbridge Medical Technology Co (FRA:818) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Zylox-Tonbridge Medical Technology Co Return-on-Tangible-Equity Related Terms
Zylox-Tonbridge Medical Technology Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zylox-Tonbridge Medical Technology Co Return-on-Tangible-Equity Chart
FRA:818 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Zylox-Tonbridge Medical Technology Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zylox-Tonbridge Medical Technology Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zylox-Tonbridge Medical Technology Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Zylox-Tonbridge Medical Technology Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 7.90% mean?
Zylox-Tonbridge Medical Technology Co (FRA:818) has a Return-on-Tangible-Equity of 7.90% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zylox-Tonbridge Medical Technology Co and its competitors. According to the industry distribution chart, Zylox-Tonbridge Medical Technology Co ranks #305 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 40.3%.
Is Zylox-Tonbridge Medical Technology Co's Return-on-Tangible-Equity too high?
Zylox-Tonbridge Medical Technology Co's current Return-on-Tangible-Equity is 7.90%. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.09. Zylox-Tonbridge Medical Technology Co's value of 7.90% is 93.2% above this industry median. Based on the distribution chart, Zylox-Tonbridge Medical Technology Co ranks #305 out of 757 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Zylox-Tonbridge Medical Technology Co has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zylox-Tonbridge Medical Technology Co's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zylox-Tonbridge Medical Technology Co ranks #305 out of 757 companies for Return-on-Tangible-Equity. This puts Zylox-Tonbridge Medical Technology Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.09. Zylox-Tonbridge Medical Technology Co's value of 7.90% is 93.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.09, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zylox-Tonbridge Medical Technology Co's current Return-on-Tangible-Equity of 7.90% is 93.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zylox-Tonbridge Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zylox-Tonbridge Medical Technology Co's current Return-on-Tangible-Equity is 7.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zylox-Tonbridge Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co (FRA:818) is currently considered Significantly Undervalued. The stock's GF Value™ is €3.72, compared to a current price of €2.08 — trading 44.1% below its estimated fair value. The current Return-on-Tangible-Equity is 7.90% and 93.2% above the Medical Devices & Instruments industry median of 4.09. Zylox-Tonbridge Medical Technology Co's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Zylox-Tonbridge Medical Technology Co (FRA:818), the current Return-on-Tangible-Equity is 7.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zylox-Tonbridge Medical Technology Co (FRA:818) Overvalued in 2026?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co stock appears to be undervalued.
The current stock price of €2.08 is trading 44.1% below its estimated GF Value™ of €3.72.
GuruFocus considers Zylox-Tonbridge Medical Technology Co to be Significantly Undervalued.
Key valuation signals for FRA:818:
Return-on-Tangible-Equity: 7.90%
GF Value™: €3.72 vs. price of €2.08 (44.1% below fair value)
Industry Position: 93.2% above the Medical Devices & Instruments median (#305 of 757)
No single metric tells the full story. See the FRA:818 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's products include Thrombite Clot Retriever Device (Thrombite CRD), Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB), and others. The company derives majority of its revenue from PRC.
76GF Score
Get the complete analysis for FRA:818
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:818 has been successfully added to your 
